BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li Y, Dong Q, Cui Y. Synergistic inhibition of MEK and reciprocal feedback networks for targeted intervention in malignancy. Cancer Biol Med 2019;16:415-34. [PMID: 31565475 DOI: 10.20892/j.issn.2095-3941.2019.0137] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
Number Citing Articles
1 Nakai C, Mimaki S, Matsushima K, Shinozaki E, Yamazaki K, Muro K, Yamaguchi K, Nishina T, Yuki S, Shitara K, Bando H, Suzuki Y, Akagi K, Nomura S, Fujii S, Sugiyama M, Nishida N, Mizokami M, Koh Y, Koshizaka T, Okada H, Abe Y, Ohtsu A, Yoshino T, Tsuchihara K. Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant. Int J Clin Oncol 2023. [PMID: 36856908 DOI: 10.1007/s10147-023-02318-w] [Reference Citation Analysis]
2 Li Y, Cui J, Li C, Deng C, Deng G, Zhang H, An F. Biomaterial-assisted photoimmunotherapy for synergistic suppression of cancer progression. Chinese Chemical Letters 2023. [DOI: 10.1016/j.cclet.2023.108180] [Reference Citation Analysis]
3 Hu J, Gao J, Fang X, Liu Z, Wang F, Huang W, Wu H, Zhao G. DTSyn: a dual-transformer-based neural network to predict synergistic drug combinations. Brief Bioinform 2022:bbac302. [PMID: 35915050 DOI: 10.1093/bib/bbac302] [Reference Citation Analysis]
4 Jain AS, Prasad A, Pradeep S, Dharmashekar C, Achar RR, Ekaterina S, Victor S, Amachawadi RG, Prasad SK, Pruthvish R, Syed A, Shivamallu C, Kollur SP. Everything Old Is New Again: Drug Repurposing Approach for Non-Small Cell Lung Cancer Targeting MAPK Signaling Pathway. Front Oncol 2021;11:741326. [PMID: 34692523 DOI: 10.3389/fonc.2021.741326] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
5 Li Y, Zhang C, Li G, Deng G, Zhang H, Sun Y, An F. Protease-triggered bioresponsive drug delivery for the targeted theranostics of malignancy. Acta Pharm Sin B 2021;11:2220-42. [PMID: 34522585 DOI: 10.1016/j.apsb.2021.01.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
6 Chua V, Mattei J, Han A, Johnston L, LiPira K, Selig SM, Carvajal RD, Aplin AE, Patel SP. The Latest on Uveal Melanoma Research and Clinical Trials: Updates from the Cure Ocular Melanoma (CURE OM) Science Meeting (2019). Clin Cancer Res 2021;27:28-33. [PMID: 33060121 DOI: 10.1158/1078-0432.CCR-20-2536] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
7 Bugide S, Parajuli KR, Chava S, Pattanayak R, Manna DLD, Shrestha D, Yang ES, Cai G, Johnson DB, Gupta R. Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1R. Oncogenesis 2020;9:44. [PMID: 32371878 DOI: 10.1038/s41389-020-0228-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
8 Li Y, Xin J, Sun Y, Han T, Zhang H, An F. Magnetic resonance imaging-guided and targeted theranostics of colorectal cancer. Cancer Biol Med 2020;17:307-27. [PMID: 32587771 DOI: 10.20892/j.issn.2095-3941.2020.0072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Reference Citation Analysis]